Targeted News Service logo

-- Preview Email Newsletter
Public Policy Tipoffs Involving New Hampshire Newsletter for 2026-10-25 ( 10 items )  
Public Policy Tipoffs Involving New Hampshire
1Day Sooner Calls on FDA to Broaden Public Release of Complete Response Letters and Adopt AI Redaction Tools (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. October 7, 2026 Kyle Diamantas, J.D. Acting Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Re: Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments [Docket No. FDA-2026-N-8163] Dear Acting Commissioner Diamantas, 1Day Sooner appreciates the opportunit more ST
3 Organizations Urge FDA to Maintain Access to Mifepristone and Support Role of Advanced Practice Clinicians (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. October 6, 2026 Kyle A. Diamantas, JD Acting Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Ave. Silver Spring, MD 20993 Comment of Advanced Practice Clinician Professional Associations in Support of the Following Citizen Petitions: FDA-2025-P-0377-0001 FDA-2025 P-0377-0250 FDA-2025-P-1576-0001 FDA-2025-P-3287-0001 FDA-2025- more ST
American Academy of Ophthalmology Urges FDA to Approve Atropine Solution to Combat Rising Myopia Rates in Children (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. 20 F Street NW Suite 400 Washington, DC 20001-6701 P.O. Box 7424 San Francisco, CA 94120-7424 T: +1 202.737.6662 aao.org October 19, 2026 LaToya Bonner Center for Drug Evaluation and Research (CDER) Food and Drug Administration (FDA) 10903 New Hampshire Ave., Bldg. 31, Rm. 2417 Silver Spring, MD 20993-0002 FDA-2026-N-10606 Dermatologic and Ophthalmic Dru more ST
Biotechnology Innovation Organization: Risk-Based Approach to Container Closure Systems Guidance Emphasizes Flexibility and Clarity (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. October 13, 2026 U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Re: Docket No. FDA-2026-D-7957; Container Closure Systems for Human Drugs and Biological Products Dear Recipient: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Agency's draf more ST
Huntingtons Disease Society Praises FDA Commitment to Accelerate Rare Disease Therapies and Incorporate Patient Experience (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. October 9, 2026 Kyle Diamantas, J.D. Acting Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Docket No. FDA-2026-N-8163 Subject: Public Comment on the Reauthorization of the Prescription Drug User Fee Act (PDUFA VIII Commitment Letter) Dear Acting Commissioner Diamantas, The Huntington's Diseas more ST
National Multiple Sclerosis Society Urges FDA to Strengthen Workforce and Modernize Regulatory Science to Accelerate MS Therapies (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. October 16, 2026 Emily Ewing U.S. Food and Drug Administration Department of Health and Human Services 10903 New Hampshire Avenue Silver Spring, MD 20993 Submitted via regulations.gov RE: Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments (Docket No. FDA-2026-N-8163) Dear Ms. Ewing, The National Multiple Sclerosis  more ST
National Wildlife Federation Opposes Proposed Rollback of Federal Water Protections Threatening Wetlands and Streams (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. October 9, 2026 Stacey Jensen Oceans, Wetlands and Communities Division Office of Water (4504- T) Environmental Protection Agency 1200 Pennsylvania Avenue NW Washington, DC 20460 CWAwotus@epa.gov Milton Boyd Office of the Assistant Secretary of the Army for Civil Works Department of the Army 108 Army Pentagon Washington, DC 20310-0104 usarmy.pentagon.hqda-asa- more ST
New England Fishermen's Stewardship Association Urges Practical, Targeted Approaches to Whale Conservation (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. Page 1 of 11 New England Fishermen's Stewardship Association 500 Southborough Dr. Suite 204 South Portland, ME 04106 October 16, 2026 Jennifer Goebel Atlantic Large Whale Take Reduction Team Coordinator National Marine Fisheries Service Greater Atlantic Regional Fisheries Office 55 Great Republic Drive Gloucester, MA 01930 Re: Atlantic Large Whale Take Reduction more ST
Patients For Affordable Drugs Advocate for Increased FDA Action to Accelerate Generic Drug Approvals and Lower Prices (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. The Honorable Kyle Diamantas Acting Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 October 15, 2026 Re: Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments (Docket No. FDA-2025-N-0873) Dear Acting Commissioner Diamantas: Patients For Affordable Drugs (P4AD) apprec more ST
Patients For Affordable Drugs Advocate for Lower Drug Prices and Improved Access in PDUFA Reauthorization (10)
WASHINGTON, Oct. 24 -- In response to a federal agency request for information, the following public comment letter was submitted electronically to the regulations.gov site. The Honorable Kyle Diamantas Acting Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 October 15, 2026 Re: Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments (Docket No. FDA-2026-N-8163) Dear Acting Commissioner Diamantas: Patients For Affordable Drugs (P4AD) appreciates the op more ST